Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review
A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.
Source: psychiatrictimes.com
Johan Luthman News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Johan Luthman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Johan Luthman Today - Breaking & Trending Today
Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of
Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap...
Source: pharmiweb.com
Longwood Healthcare Leaders San Francisco CEO to Convene Life Science ...
Longwood Healthcare Leaders San Francisco CEO to Convene Life Science ...
Source: pr-inside.com
JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for
New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home...
Source: pharmiweb.com
Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache Society
Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity...
Source: pharmiweb.com